Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
AssigneesThe Broad Institute, Inc., The Brigham and Women's Hospital, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital, Dana-Farber Cancer Institute, Inc.
InventorsBradley E. Bernstein, Jon C. Aster, James E. Bradner, Birgit Knoechel, Christopher J. Ott, David Root
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of treatment and diagnosis of subjects with cancer. In some aspects, the invention relates to methods of treatment and diagnosis of subjects with cancer, wherein the cancer is characterized by a Notch pathway activation mutation or by resistance to a Notch pathway inhibitor.
Claims55
A method comprising:
- administering to a subject having cancer
- (i) a bromodomain inhibitor and/or
- (ii) a Bcl-2 inhibitor, and
- a Notch pathway inhibitor, in an effective amount to treat the cancer.
A method comprising:
- administering to a subject having cancer
- (i) a bromodomain inhibitor and/or
- (ii) a Bcl-2 inhibitor,
- in an effective amount to treat the cancer, wherein the cancer is characterized by the presence of a Notch pathway activation mutation.
A method comprising:
- administering to a subject having cancer
- (i) a bromodomain inhibitor and/or
- (ii) a Bcl-2 inhibitor
- in an effective amount to treat the cancer, wherein the cancer is resistant to treatment with a Notch pathway inhibitor.
A method comprising:
- administering to a subject having cancer
- (i) a bromodomain inhibitor and/or
- (ii) a Bcl-2 inhibitor
- in an effective amount to treat the cancer, wherein the cancer is characterized by abnormal increased HPI level, wherein the HPI level is HPI-alpha level, HPI-beta level and/or HPI-gamma level.
A method comprising:
- (a) measuring nucleus size in a tumor sample from a subject;
- and
- (b) comparing nucleus size in the tumor sample to a control,
- wherein a decreased nucleus size in the tumor sample compared to the control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor.
A method comprising:
- (a) measuring HPI level in a tumor sample from a subject;
- and
- (b) comparing the HPI level in the tumor sample to a control,
- wherein an increased HPI level in the tumor sample compared to the control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor,
- wherein the HPI level is HPI-alpha level, HPI-beta level, and/or HPI-gamma level.
A method comprising:
- (a) measuring level of a chromatin state biomarker (CSB) in a tumor sample from a subject, the CSB selected from:
- (i) a first CSB group consisting of NPM1, NARG1, RCC1, SSRP1, PRMT3, SAP30, CBX6, CHMP2B, UBE2M, WDR77, HMGB1, CARM1, USP13, HDAC4, COQ3, SET, GATAD2A, PRMT6, HMG20B, DNMT1, ADA, SS18, UBE3A, ZMYND11, and NOC2LL (“Group I CSB”);
- and
- (ii) a second CSB group consisting of UTX, SIN3A, SAP30L, FLJ20309, RCOR2, ARID5A, UBE2Q2, TRIM24, BAZ2B, SMYD3, EZH2, PHF1, PHF2, BCR, SMARCD3, BMI1, CHD6, FBXL11, SIRT7, ASF1A, RCOR3, CBX4, EPC1, BRD1, and BNF11 (“Group II CSB”);
- and
- (b) comparing the Group I and/or Group II CSB level with a control, wherein a Group I CSB level that is reduced in the tumor sample compared to a control and/or a Group II CSB level that is elevated in the tumor sample compared to a control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor.
A method comprising:
- (a) measuring a level of a biomarker in a tumor sample from a subject, the biomarker selected from DTX1, HES4, CD1d, ETS1, ETV6, Runx1, Bcl-2, MYC and CD52;
- and
- (b) comparing the biomarker level with a control,
- wherein a level of DTX1, HES4, or CD1d that is reduced in the tumor sample compared to the control and/or a level of ETS1, ETV6, Runx1, CD52, MYC or Bcl-2 that is elevated in the tumor sample compared to the control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor.
A method comprising:
- (a) measuring a level of histone modification in a tumor sample from a subject, the histone modification selected from H3K27me3 and H3K9me3;
- and
- (b) comparing the histone modification level with a control,
- wherein a level of histone modification that is elevated in the tumor sample compared to the control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor.
A method comprising:
- (a) measuring a level of H3K27Ac histone modification in a tumor sample from a subject;
- and
- (b) comparing the H3K27Ac histone modification level with a control, wherein a level of H3K27Ac histone modification that is reduced in the tumor sample compared to the control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor.
A method comprising:
- (a) measuring a level of H3K4me1 histone modification at a site of elevated H3K27Ac histone modification;
- and
- (b) comparing the H3K4me1 histone modification level with a control, wherein a level of H3K4me1 histone modification at a site of elevated H3K27Ac histone modification that is elevated in the tumor sample compared to the control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor.
A method comprising:
- administering to a subject having cancer an inhibitor of ARID3B, EZH2, PRMT2, SND1, BRD1, SUV39H1, PRMT5, SS18, BRD4, KDM5D, PRMT7, STAG3L1, CD2BP2, MLL5, SUDS3, CHD1, MINA, CHD8, MORF4L1, or CHRAC1, wherein the cancer is resistant to a Notch pathway inhibitor.
Dependencies are inferred from the claim text.